BGASoft's AGILEPART11 tool allows FDA regulated companies to manage product portfolio

NewsGuard 100/100 Score

BGASoft, a global leader in the development industry has once again left their competitors in the dust. The introduction of BGASoft's new AGILEPART11 is like no other on the market today, and will make using AGILE process while maintaining 21 CFR Part 11 compliance a snap for FDA regulated companies.

The AGILEPART11 not only replaces a variety of tools, but eliminates the production of non-viable software. Unlike any other AGILE tool available, AGILEPART11 from BGASoft provides for the ability to manage product portfolio according to the 21 Code of Federal Regulations Part 11.

The genius behind the innovative AGILEPART11 is the CEO of BGASoft, Mr. Gabriel Balint. His understanding of the needs of FDA regulated companies is second to none in the industry. Mr. Balint stated "At BGASoft, we take the time to listen to the needs of our clients. This is why we created the AGILEPART11. Our clients wanted one AGILE tool that would handle a multitude of functions, as well as comply with 21 CFR Part 11. We simply stepped up to the plate, and gave them what they needed to get their jobs done easier."

There are nothing but glowing comments from the users of BGASoft's new AGILEPART11. Mr. Pete Tearle, the IT Director, Clinical Trials at med fusion said "We have started using AgilePart11 for requirements gathering, and are already seeing returns. We are very pleased with the product and looking forward to seeing how we can implement it for our entire application portfolio." Many others have seen the same success with AGILEPART11. BGASoft is now offering this innovative AGILE tool worldwide.

 

Source:

BGASoft Inc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.